(2R,4R) -LY3372689
O-GlcNAcase-IN-4 is a O-GlcNAcase inhibitor extracted from patent WO2018140299A1 Formulaic Ic. O-GlcNAcase-IN-4 can be used for the research of neurodegenerative diseases and disorders, such as Alzheimer's disease[1].
Product Specifications
UNSPSC
12352005
Target
OGA
Type
Reference compound
Related Pathways
Neuronal Signaling
Applications
Neuroscience-Neurodegeneration
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/2r-4r-ly3372689.html
Solubility
10 mM in DMSO
Smiles
CC(NC1=NC(F)=C(S1)CN2[C@@H](C[C@@H](CC2)OCC3=NOC(C)=N3)C)=O
Molecular Formula
C16H22FN5O3S
Molecular Weight
383.44
References & Citations
[1]Dreyfus NJF, et, al. N-[4-fluoro-5-[[ (2s,4s) -2-methyl-4-[ (5-methyl-1,2,4-oxadiazol-3-yl) methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor. WO2018140299A1.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
244240-PE 100 µL
CASP4 (Caspase 4, Apoptosis-Related Cysteine Peptidase, ICE (rel) II, ICEREL-II, ICH-2, Mih1/TX, TX) (PE)
Ask
View Details Z0773-ML750 100 µL
ZO-3, CT (Tight Junction-associated Polypeptide, Zonula Occludens 3) (MaxLight 750) discontinued
Ask
View Details